Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study unconfirmed

Story checked

Long-term follow-up tracks benefits and risks of stem cell transplants for severe systemic sclerosis (opens in a new tab)

medicalxpress.com · 2026-10-29

Short answerEvidenceSource

Short answer

Source study unconfirmed

Study not confirmed.

The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.

15 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

No single source study could be confirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

View article claims
3

Search result

Source study unconfirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

  • Also referencedpresented as the new finding

    Long-term evaluation of the effectiveness and safety of autologous haematopoietic stem-cell transplantation for systemic sclerosis (NISSC1-LTE): a cohort study

The literature search

15 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 11 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 6Not checkedAn international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation for early severe systemic sclerosis, suggesting sustained positive clinical outcomes and long-term safety.View evidenceHide evidence

As stated60% progression-free survival at 10 years

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 6Not checkedThe NISSC1-LTE study is described as the first international prospective study providing long-term results on autologous HCT in patients with early severe systemic sclerosis, following 80 patients for a median of 9.2 years after transplantation.View evidenceHide evidence

As stated80 patients; median follow-up 9.2 years

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 6Not checkedAt 10 years, estimated progression-free survival was 60% and overall survival was 71%, and 34 of 80 patients were alive without needing further immunosuppressive treatment at last follow-up.View evidenceHide evidence

As stated60% PFS; 71% overall survival; 34 of 80 patients

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 6Not checkedThe median modified Rodnan skin score fell from 24 at baseline to 6 at five years and 5 at 10 years, while lung function measures were largely stable over time.View evidenceHide evidence

As statedRodnan skin score 24 to 5; FVC 72% to 71%; DLCO 59% to 61%

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 6Not checkedEighteen patients died during follow-up, including five early deaths attributed to HCT, nine to disease progression, two to post-HCT malignancies and two to late serious infections; estimated nonrelapse mortality at 10 years was 13%.View evidenceHide evidence

As stated18 deaths; 13% nonrelapse mortality at 10 years

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 6 of 6Not checkedThe article says the study was observational and without a control group, so it does not directly compare HCT with alternative treatments; it also notes incomplete longitudinal data and 12 patients lost to follow-up.View evidenceHide evidence

As stated12 lost to follow-up

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Plasma Cells in the Cellular Product Impact Progression Free Survival (PFS) but Not Overall Survival (OS) after Autologous (Auto) Hematopoietic Cell Transplant (HCT)

Transplantation and Cellular Therapy · 2022 · Crossref

Source (opens in a new tab)
Candidate

Chromosome 1 Abnormalities Predict Shortened Progression Free and Overall Survival in Patients with High Risk Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation, a Retrospective Analysis

Journal of Blood & Lymph · 2014 · Crossref

Source (opens in a new tab)

Explore all search results